where challenging its conclusions is tantamount to working for the tobacco industry. Anyone who does challenge the conclusions of the movement is attacked and accused of being a tobacco industry mole or sympathizer. Thus, there is little threat that conclusions of anti-smoking researchers or groups will be challenged in the first place or that if challenged, the individual criticizing the conclusions will be taken seriously. Ironically, the Rest of the Story is one of the only watchdogs there is to monitor the quality of science in tobacco control. In the long run, I believe the tobacco companies made a wise decision. First, they help shed their public image as corporations that are undermining the scientific conclusions of the health community. Second, by letting the anti-smoking groups run rampant, they probably realize that these groups will eventually destroy their own credibility by making more and more outlandish statements, until finally, the public loses faith in the scientific integrity of these anti-smoking groups. Ironically, the tobacco companies actually have a lot more legitimate criticisms of the validity of anti-smoking groups' scientific claims now than they did during the time when the companies were actually challenging these claims. Bupropion and its Main Metabolite Reverse Nicotine Chronic Tolerance in the Mouse The issue also includes a summary review article of the significance of this research for the development of new smoking cessation drugs, which features as its example of the implications of this line of research the development of the nicotine vaccine. The Rest